Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer

• A. Fernández Montes ^[1] ; E. Élez ^[2] ; A. Vivancos ^[2] ; N. Martínez ^[3] ; P. González ^[7] ; M. Covela ^[4] ; J. de la Cámara ^[8] ; A. Cousillas ^[5] ; J. C. Méndez ^[9] ; B. Graña ^[3] ; E. Aranda ^[6]
  1. [1] Complexo Hospitalario Universitario de Ourense

     Complexo Hospitalario Universitario de Ourense

     Ourense, España

     
  2. [2] Universitat Autònoma de Barcelona

     Universitat Autònoma de Barcelona

     Barcelona, España

     
  3. [3] Complexo Hospitalario Universitario da Coruña

     Complexo Hospitalario Universitario da Coruña

     A Coruña, España

     
  4. [4] Hospital Universitario Lucus Augusti

     Hospital Universitario Lucus Augusti

     Lugo, España

     
  5. [5] Complexo Hospitalario Universitario de Pontevedra

     Complexo Hospitalario Universitario de Pontevedra

     Pontevedra, España

     
  6. [6] Hospital Universitario Reina Sofia

     Hospital Universitario Reina Sofia

     Cordoba, España

     
  7. [7] Medical Oncology Department, Hospital Universitario Álvaro Cunqueiro, Vigo, Spain
  8. [8] Medical Oncology Department, Hospital Universitario Arquitecto Marcide, Ferrol, Spain
  9. [9] Medical Oncology Department, Centro Oncológico de Galicia, A Coruña, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 6 (junio), 2022, págs. 1209-1214
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • Purpose Some patients with histologically confirmed primary mCRC and mutated RAS reported undetectable RAS mutant clones in plasma after receiving anti-VEGF treatment. The aim was to prospectively assess it with its potential therapeutic implications.

    Methods RAS mutant genes in solid biopsy (before first-line treatment: FOLFOX/CAPOX + bevacizumab) were compared in liquid biopsy (before second-line treatment: panitumumab + FOLFIRI), using Idylla™ system. Discordant results between solid/liquid biopsies were assessed by the next-generation sequencing (NGS) test (solid/liquid biopsies).

    Results Twenty-three patients were assessed (seven had RAS mutant discrepancies between solid/liquid biopsies). The NGS test confirmed that 3/23 (13%) patients had undetectable RAS mutant clones in liquid biopsy and 3/23 (13%) presented discrepancies in solid biopsy (Idylla™ system vs. NGS test).

    Conclusion Thirteen percentage of patients had undetectable RAS mutant clones in liquid biopsy after first-line treatment. However, some discrepancies between solid and liquid biopsies have been observed. These results suggest a need to improve accuracy of RAS analyses, especially in solid biopsies.